Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
500.19
-0.96 (-0.19%)
At close: May 5, 2025, 4:00 PM
485.00
-15.19 (-3.04%)
After-hours: May 5, 2025, 4:35 PM EDT
Vertex Pharmaceuticals Stock Forecast
Stock Price Forecast
The 23 analysts with 12-month price forecasts for Vertex Pharmaceuticals stock have an average target of 512.3, with a low estimate of 420 and a high estimate of 586. The average target predicts an increase of 2.42% from the current stock price of 500.19.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Vertex Pharmaceuticals stock from 25 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 12 | 10 | 10 | 10 | 10 | 10 |
| Buy | 8 | 7 | 6 | 6 | 6 | 6 |
| Hold | 9 | 9 | 9 | 9 | 9 | 9 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 0 | 0 | 0 | 0 |
| Total | 30 | 27 | 25 | 25 | 25 | 25 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $535 | Buy | Initiates | $535 | +6.96% | Apr 22, 2025 |
| RBC Capital | RBC Capital | Hold Maintains $408 → $420 | Hold | Maintains | $408 → $420 | -16.03% | Apr 1, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $555 → $567 | Strong Buy | Maintains | $555 → $567 | +13.36% | Mar 31, 2025 |
| RBC Capital | RBC Capital | Hold Maintains $407 → $408 | Hold | Maintains | $407 → $408 | -18.43% | Feb 20, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Sell → Hold Upgrades $408 → $424 | Strong Sell → Hold | Upgrades | $408 → $424 | -15.23% | Feb 12, 2025 |
Financial Forecast
Revenue This Year
12.21B
from 11.02B
Increased by 10.78%
Revenue Next Year
13.40B
from 12.21B
Increased by 9.75%
EPS This Year
18.46
from -2.08
EPS Next Year
20.99
from 18.46
Increased by 13.71%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 13.1B | 15.2B | 16.6B | ||
| Avg | 12.2B | 13.4B | 14.6B | ||
| Low | 11.3B | 11.6B | 11.6B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 18.6% | 24.1% | 24.1% | ||
| Avg | 10.8% | 9.7% | 8.8% | ||
| Low | 2.9% | -4.9% | -13.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 20.56 | 28.70 | 35.07 | ||
| Avg | 18.46 | 20.99 | 23.42 | ||
| Low | 16.41 | 17.52 | 18.70 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 55.5% | 67.1% | ||
| Avg | - | 13.7% | 11.6% | ||
| Low | - | -5.1% | -10.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.